Galectin Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

NORCROSS, Ga., Sept. 05, 2017 -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Tuesday, September 12 at 11:40 a.m. ET. The conference is being held September 10-12, 2017 at the New York Palace Hotel in New York, NY.

A live webcast of the presentation may be accessed on the Investor Relations section of the Galectin Therapeutics website at www.galectintherapeutics.com. A replay of the webcast will be available after the event.

In addition to the presentation, management will take part in a series of 1x1 and small group meetings. If you would like to attend the conference, or to request a 1x1 meeting, please visit www.rodmanevents.com to register. The Global Investment Conference will feature more than 300 public and private companies from around the world, with over 2,000 attendees anticipated.

About Galectin Therapeutics
Galectin Therapeutics is developing promising therapies for the treatment of fibrotic liver disease, skin diseases, and cancer based on the Company's unique understanding of galectin proteins, which are key mediators of biologic function. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. The Company is pursuing a development pathway to clinical enhancement and commercialization for its lead compounds in liver fibrosis and cancer. Additional information is available at www.galectintherapeutics.com.

Contacts: 
Jack Callicutt, Chief Financial Officer 
(678) 620-3186
[email protected]